Accessibility Statement Skip Navigation
  • Resources
  • Blog
  • Journalists
  • +44 (0)20 7454 5110
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All Public Company News
      • All Multimedia News
      • View All News Releases

      • Regulatory News

      • D/A/CH Regulatory News
      • UK Regulatory News
      • View All Regulatory News

  • Business & Money
      • Auto & Transportation

      • Aerospace & Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads & Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking & Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers & Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalisation
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls & Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil & Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defence
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation & Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking & Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers & Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines & Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics & Personal Care
      • Fashion
      • Food & Beverages
      • Furniture & Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewellery
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film & Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks & Tourist Attractions
      • Gambling & Casinos
      • Hotels & Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Animal Welfare
      • Corporate Social Responsibility
      • Economic News, Trends & Analysis
      • Education
      • Environmental
      • European Government
      • Labour & Union
      • Natural Disasters
      • Not For Profit
      • Public Safety
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Overview
  • Distribution
  • Paid Placement
  • Multichannel Amplification
  • Disclosure Services
  • SocialBoost
  • Rooms
    • MediaRoom
    • ESG Rooms
  • AI Tools
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Hamburger menu
  • Cision PR Newswire UK provides press release distribution, targeting, monitoring, and marketing services
  • Send a Release
    • Phone

    • +44 (0)20 7454 5110 from 8 AM - 5:30 PM GMT

    • ALL CONTACT INFO
    • Contact Us

      +44 (0)20 7454 5110
      from 8 AM - 5:30 PM GMT

  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • News in Focus
    • Browse News Releases
    • Regulatory News
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
    • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • Overview
  • Distribution
  • Paid Placement
  • Multichannel Amplification
  • Disclosure Services
  • Cision Communications Cloud®
  • AI Tools
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists
  • General Enquiries
  • Media Enquiries
  • Partnerships
  • Client Login
  • Send a Release
  • Resources
  • Blog
  • Journalists

Epidermolysis Bullosa Market to Surge at a CAGR of ~8% During the Study Period (2019-2032), Predicts DelveInsight

This image opens in the lightbox

News provided by

DelveInsight Business Research, LLP

10 Aug, 2023, 21:01 GMT

Share this article

Share toX

Share this article

Share toX

The epidermolysis bullosa market size is anticipated to increase during the forecast period (2023–2032) owing to the increase in the clinical and genetic testings, recent approvals of potential gene-based cell therapies, and expected launch of emerging therapies into the epidermolysis bullosa market. 

LAS VEGAS, Aug. 10, 2023 /PRNewswire/ -- DelveInsight's Epidermolysis Bullosa Market Insights report includes a comprehensive understanding of current treatment practices, epidermolysis bullosa emerging drugs, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into 7MM [the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan].

Key Takeaways from the Epidermolysis Bullosa Market Report

  • As per DelveInsight analysis, the epidermolysis bullosa market size in the 7MM was approximately USD 1.5 billion in 2022.
  • According to the assessment done by DelveInsight, the estimated total prevalent epidermolysis bullosa cases in the 7MM were approximately 46K in 2022. 
  • Epidermolysis is more prevalent in children and young adults as ~78% cases were in the age group of <19 years in the 7MM in 2019.
  • VYJUVEK is the only FDA-approved therapy in the US, and FILSUVEZ is the only approved therapy in the EU, which is available in Germany only. Japan also has one approved cell therapy for epidermolysis bullosa with the name of JACE.
  • Among all the therapies VYJUVEK is expected to capture the largest market share followed by EB-101 and FILSUVEZ by 2032 in the 7MM.
  • Leading epidermolysis bullosa companies such as Abeona Therapeutics, Castle Creek Biosciences, RHEACELL, Ishin Pharma, Holostem Terapie Avanzate, BridgeBio (Phoenix Tissue Repair), InMed Pharmaceuticals, Shionogi, Anterogen, and others are developing novel epidermolysis bullosa drugs that can be available in the epidermolysis bullosa market in the coming years.
  • The promising epidermolysis bullosa therapies in the pipeline include EB-101, D-Fi (dabocemagene autoficel), ABCB5+ mesenchymal stem cells (ABCB5+ MSCs), ISN001, RV-LAMB3-transduced epidermal stem cells, PTR-01, INM-755, Redasemtide, ALLO-ASC-SHEET, and others.

Discover which therapies are expected to grab the major epidermolysis bullosa market share @ Epidermolysis Bullosa Market Report

Epidermolysis Bullosa Overview

Epidermolysis bullosa is a rare, inherited genetic disorder that affects the skin and mucous membranes. It belongs to a group of disorders known as "blistering skin diseases." Epidermolysis bullosa is characterized by extreme skin fragility, causing the skin to be exceptionally sensitive to friction or trauma, leading to the formation of painful blisters and sores. The primary cause of epidermolysis bullosa is genetic mutations that affect the production of proteins responsible for holding the layers of the skin together.

The hallmark symptom of epidermolysis bullosa is the development of blisters on the skin and mucous membranes, often triggered by minor friction or pressure. These blisters can occur on any part of the body, both external and internal, and can be painful and prone to infection. In severe cases, the blisters may lead to chronic wounds, scarring, and deformities. Diagnosing epidermolysis bullosa involves a combination of clinical examination, family history assessment, and skin biopsy. The doctor will carefully examine the patient's skin and note the characteristic blistering patterns.

Epidermolysis Bullosa Epidemiology Segmentation

DelveInsight estimates that there were approximately 46K prevalent cases of epidermolysis bullosa in the 7MM in 2022.

The United States contributed to the largest prevalent cases of epidermolysis bullosa, accounting for ~65% of the 7MM in 2022. Whereas EU4 and the UK, and Japan accounted for around 30% and ~5% of the total population share, respectively, in 2022.

The epidermolysis bullosa market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

  • Total Epidermolysis Bullosa Prevalent Cases
  • Total Epidermolysis Bullosa Diagnosed Prevalent Cases
  • Epidermolysis Bullosa Cases  by Gender
  • Epidermolysis Bullosa Cases by Age
  • Epidermolysis Bullosa Type-specific Cases

Epidermolysis Bullosa Treatment Market 

Currently, there is no cure for epidermolysis bullosa, and treatments primarily focus on managing symptoms and improving patients' quality of life. The main goal of epidermolysis bullosa treatment is to prevent or reduce blistering, promote wound healing, and manage associated complications, such as infection and pain. Wound care is a fundamental aspect of epidermolysis bullosa management, involving gentle handling of the skin, dressing changes, and meticulous wound cleaning to minimize the risk of infection. Advanced wound dressings and bandages are used to protect the affected areas and provide a supportive environment for healing. Pain management is crucial, and pain relief medications, including topical anesthetics and systemic analgesics, are often prescribed to alleviate discomfort.

In recent years, there has been significant progress in research and the development of innovative therapies for epidermolysis bullosa. Gene therapy and other experimental approaches hold promise for potential future treatments. Clinical trials investigating gene-editing techniques, such as CRISPR-Cas9, have shown encouraging results in preclinical models. Moreover, cell-based therapies, such as stem cell transplants, are being explored as potential treatments for epidermolysis bullosa.

To manage complications and enhance the overall well-being of epidermolysis bullosa patients, a multidisciplinary approach is crucial. This involves a team of healthcare professionals, including dermatologists, wound care specialists, pain management experts, nutritionists, and psychologists, working collaboratively to address the various aspects of the condition. While significant strides have been made in understanding and treating epidermolysis bullosa, continued research and funding are essential to improve existing therapies and eventually find a cure for this challenging and life-altering disease.

To know more about epidermolysis bullosa treatment guidelines, visit @ Epidermolysis Bullosa Management 

Epidermolysis Bullosa Pipeline Therapies and Key Companies

  • EB-101: Abeona Therapeutics
  • D-Fi (dabocemagene autoficel): Castle Creek Biosciences
  • ABCB5+ mesenchymal stem cells (ABCB5+ MSCs): RHEACELL
  • ISN001: Ishin Pharma
  • RV-LAMB3-transduced epidermal stem cells: Holostem Terapie Avanzate
  • PTR-01: BridgeBio (Phoenix Tissue Repair)
  • INM-755: InMed Pharmaceuticals
  • Redasemtide: Shionogi
  • ALLO-ASC-SHEET: Anterogen

Learn more about the FDA-approved drugs for epidermolysis bullosa @ Drugs for Epidermolysis Bullosa Treatment 

Epidermolysis Bullosa Market Dynamics

The epidermolysis bullosa market dynamics have witnessed significant changes in recent years. As awareness about this condition has increased, there has been a surge in early diagnosis and better disease management, leading to a growing patient population seeking treatment options. This has subsequently attracted increased research and development activities by pharmaceutical companies and biotechnology firms, resulting in the emergence of potential novel therapies.

The epidermolysis bullosa treatment market has become more competitive, with several companies vying to develop innovative products, including gene therapies, cell-based therapies, and advanced wound care products. Regulatory agencies have also become more proactive in facilitating the development and approval of epidermolysis bullosa treatments, which has further accelerated the pace of progress.

However, challenges persist, primarily related to the high cost of research and development for rare diseases like epidermolysis bullosa and the limited patient pool. Pricing and reimbursement complexities for novel therapies have also been obstacles, impacting their accessibility to patients worldwide. Additionally, there is a need for improved diagnostic tools and better patient support systems to ensure timely and effective treatment.

Despite these challenges, the epidermolysis bullosa market continues to show promise and growth potential, driven by scientific advancements, increased funding, and collaborative efforts among stakeholders. The ultimate goal is to alleviate the burden on epidermolysis bullosa patients and improve their quality of life through innovative and transformative therapeutic approaches. As the landscape evolves, ongoing efforts from the medical community, policymakers, and advocacy groups are critical in fostering advancements and addressing the unmet needs of individuals living with this devastating condition.

Report Metrics

Details

Study Period

2019–2032

Coverage

7MM [the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan].

Epidermolysis Bullosa Market CAGR

~8%

Epidermolysis Bullosa Market Size in 2022

USD 1.5 Billion

Key Epidermolysis Bullosa Companies

Abeona Therapeutics, Castle Creek Biosciences, RHEACELL, Ishin Pharma, Holostem Terapie Avanzate, BridgeBio (Phoenix Tissue Repair), InMed Pharmaceuticals, Shionogi, Anterogen, and others

Key Pipeline Epidermolysis Bullosa Therapies

EB-101, D-Fi (dabocemagene autoficel), ABCB5+ mesenchymal stem cells (ABCB5+ MSCs), ISN001, RV-LAMB3-transduced epidermal stem cells, PTR-01, INM-755, Redasemtide, ALLO-ASC-SHEET, and others

Scope of the Epidermolysis Bullosa Market Report

  • Therapeutic Assessment: Epidermolysis Bullosa current marketed and emerging therapies
  • Epidermolysis Bullosa Market Dynamics: Conjoint Analysis of Emerging Epidermolysis Bullosa Drugs 
  • Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
  • Unmet Needs, KOL's views, Analyst's views, Epidermolysis Bullosa Market Access and Reimbursement

Discover more about epidermolysis bullosa drugs in development @ Epidermolysis Bullosa Clinical Trials

Table of Contents

1.

Key Insights

2.

Report Introduction

3.

Executive Summary Of Epidermolysis Bullosa (EB)

4.

Key Events

5.

Epidemiology And Market Forecast Methodology

6.

Epidermolysis Bullosa Market Overview At A Glance

6.1.

Market Share (%) Distribution By Therapies In 2023

6.2.

Market Share (%) Distribution By Therapies In 2032

7.

Epidermolysis Bullosa (EB): Disease Background And Overview

7.1.

Introduction

7.2.

Causes Of Epidermolysis Bullosa

7.3.

Signs And Symptoms Of Epidermolysis Bullosa

7.4.

Pathogenesis Of Epidermolysis Bullosa

7.5.

Pathophysiology Of Itch In Epidermolysis Bullosa Skin

7.6.

Classification Of Epidermolysis Bullosa

7.7.

Genetic Bases Of Epidermolysis Bullosa

7.8.

Diagnosis Of Epidermolysis Bullosa

7.8.1.

Types Of Laboratory Referral

7.8.1.1.

Neonate With Skin Fragility

7.8.1.2.

Pediatric And Adult Patients With Skin Fragility

7.8.1.3.

Carrier Testing

7.8.1.4.

Prenatal Diagnosis

7.8.2.

Further Testing

7.8.2.1.

Skin Biopsy

7.8.2.2.

Molecular Testing

7.8.2.3.

Genetic Testing For Epidermolysis Bullosa

7.8.2.3.1.

Next–generation Sequencing (NGS) Targeted Gene Panel And Whole–exome Sequencing In Epidermolysis Bullosa

7.8.2.3.2.

Sanger Sequencing (SS)

8.

Treatment And Management Of Epidermolysis Bullosa

8.1.

Management Of Blisters

8.2.

Skin And Wound Management

8.2.1.

Management Of Epidermolysis Bullosa Simplex (EBS)

8.2.1.1.

Management Of Junctional Epidermolysis Bullosa (JEB)

8.2.1.2.

Management Of Dystrophic Epidermolysis Bullosa (DEB)

8.2.1.3.

Management Of Kindler Syndrome

9.

Guidelines

9.1.

Diagnostic Guidelines

9.1.1.

Clinical Practice Guidelines For Epidermolysis Bullosa Laboratory Diagnosis

9.1.2.

Japanese Guidelines For Diagnosis And Treatment Of Junctional And Dystrophic Epidermolysis Bullosa

10.

Epidemiology And Patient Population Of 7MM

10.1.

Key Findings

10.2.

Assumption And Rationale

10.3.

Total Prevalent Cases Of Epidermolysis Bullosa In The 7MM

10.4.

Diagnosed Prevalent Cases Of Epidermolysis Bullosa In The 7MM

10.5.

The United States

10.5.1.

Total Prevalent Cases Of Epidermolysis Bullosa In The United States

10.5.2.

Diagnosed Prevalent Cases Of Epidermolysis Bullosa In The United States

10.5.3.

Gender-Specific Cases Of Epidermolysis Bullosa In The United States

10.5.4.

Age-Specific Cases Of Epidermolysis Bullosa In The United States

10.5.5.

Type-Specific Cases Of Epidermolysis Bullosa In The United States

10.6.

EU4 And The UK

10.6.1.

Total Prevalent Cases Of Epidermolysis Bullosa In EU4 And The UK

10.6.2.

Diagnosed Prevalent Cases Of Epidermolysis Bullosa In EU4 And The UK

10.6.3.

Gender-Specific Cases Of Epidermolysis Bullosa In EU4 And The UK

10.6.4.    

Age-Specific Cases Of Epidermolysis Bullosa In EU4 And The UK

10.6.5.

Type-Specific Cases Of Epidermolysis Bullosa In EU4 And The UK

10.7.

Japan

10.7.1.

Total Prevalent Cases Of Epidermolysis Bullosa In Japan

10.7.2.

Diagnosed Prevalent Cases Of Epidermolysis Bullosa In Japan

10.7.3.

Gender-Specific Cases Of Epidermolysis Bullosa In Japan

10.7.4.

Age-Specific Cases Of Epidermolysis Bullosa In Japan

10.7.5.

Type-Specific Cases Of Epidermolysis Bullosa In Japan

11.

Patient Journey

12.

Marketed Drugs

12.1.

Key Competitors

12.2.

Vyjuvek (Beremagene Geperpavec): Krystal Biotech

12.2.1.

Product Description

12.2.2.    

Regulatory Milestones

12.2.3.

Other Developmental Activities            

12.2.4.    

Clinical Developmental Activities

12.2.4.1.

Clinical Trial Information

12.2.5.    

Safety And Efficacy

12.2.6.    

Product Profile

12.3.

Filsuvez (Oleogel-S10): Chiesi Farmaceutici

12.3.1.    

Product Description

12.3.2.

Regulatory Milestone

12.3.3.

Other Development Activities

12.3.4.    

Safety And Efficacy

12.3.5.

Product Profile

12.4.

JACE (Human Epidermal Cell Sheet): Japan Tissue Engineering

12.4.1.    

Product Description

12.4.2.    

Regulatory Milestones

12.4.3.    

Safety And Efficacy

12.4.4.

Product Profile

13.

Emerging Drugs

13.1.

Key Competitors

13.2.

EB-101: Abeona Therapeutics

13.2.1.    

Product Description

13.2.2.

Other Developmental Activities

13.2.3.    

Clinical Developmental Activities

13.2.3.1.

Clinical Trial Information

13.2.4.

Safety And Efficacy

13.3.

D-Fi (Dabocemagene Autoficel): Castle Creek Biosciences

13.3.1.    

Product Description

13.3.2.

Other Developmental Activities

13.3.3.

Clinical Developmental Activities

13.3.3.1.

Clinical Trial Information

13.3.4.

Safety And Efficacy

13.4.

ABCB5+ Mesenchymal Stem Cells (ABCB5+ MSCS): Rheacell

13.4.1.

Product Description

13.4.2.

Other Developmental Activities            

13.4.3.

Clinical Developmental Activities

13.4.3.1.

Clinical Trial Information

13.4.4.

Safety And Efficacy

13.5.

ISN001: Ishin Pharma            

13.5.1.

Product Description

13.5.2.

Other Developmental Activities

13.5.3.

Clinical Developmental Activities

13.5.3.1.

Clinical Trial Information

13.6.

RV-LAMB3-Transduced Epidermal Stem Cells: Holostem Terapie Avanzate

13.6.1.    

Product Description

13.6.2.    

Other Developmental Activities

13.6.3.    

Clinical Developmental Activities

13.6.3.1.

Clinical Trial Information

13.7.

PTR-01: Bridgebio (Phoenix Tissue Repair)

13.7.1.

Product Description

13.7.2.

Other Development Activities

13.7.3.

Clinical Development

13.7.3.1.

Clinical Trials Information

13.7.4.

Safety And Efficacy

13.8.

INM-755: Inmed Pharmaceuticals

13.8.1.

Product Description

13.8.2.

Clinical Development

13.8.2.1.

Clinical Trials Information

13.8.3.

Safety And Efficacy

13.9.       

Redasemtide: Shionogi

13.9.1.

Product Description

13.9.2.

Other Development Activities

13.9.3.    

Clinical Development

13.9.3.1.

Clinical Trials Information

13.9.4.

Safety And Efficacy

13.10.

ALLO-ASC-Sheet: Anterogen

13.10.1.

Product Description

13.10.2.

Other Developmental Activities

13.10.3.

Clinical Developmental Activities

13.10.3.1.

Clinical Trial Information

14.

Epidermolysis Bullosa: 7MM Analysis

14.1.       

Key Findings

14.2.

Market Outlook

14.3.       

Key Market Forecast Assumptions

14.4.       

Conjoint Analysis

14.5.       

Total Market Size Of Epidermolysis Bullosa In The 7MM

14.6.       

United States Market Size

14.6.1.

Total Market Size Of Epidermolysis Bullosa In The United States

14.6.2.    

Market Size Of Epidermolysis Bullosa By Current And Emerging Therapies In The United States

14.7

EU4 And The UK Market Size

14.7.1.

Total Market Size Of Epidermolysis Bullosa In EU4 And The UK

14.7.2.

Market Size Of Epidermolysis Bullosa By Current And Emerging Therapies In EU4 And The UU

14.8.       

Japan Market Size

14.8.1.    

Total Market Size Of Epidermolysis Bullosa In Japan

14.8.2.    

Market Size Of Epidermolysis Bullosa By Current And Emerging Therapies In Japan

15.

Unmet Needs

16.

Swot Analysis

17.

Kol Views

18.

Market Access And Reimbursement

18.1.       

United States

18.1.1.

Centre For Medicare & Medicaid Services (CMS)

18.2.       

EU4 And The UK

18.2.1.

Germany

18.2.2.

France

18.2.3.    

Italy

18.2.4.    

Spain

18.2.5.

United Kingdom

18.3.

Japan

18.3.1.

MHLW

18.4.       

Epidermolysis Bullosa Market Access And Reimbursement

19.

Appendix

19.1.

Bibliography

19.2.       

 Report Methodology

20.

Delveinsight Capabilities

21.

Disclaimer

Related Reports

Epidermolysis Bullosa Epidemiology Forecast

Epidermolysis Bullosa Epidemiology Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, and epidermolysis bullosa epidemiology trends.

Epidermolysis Bullosa Pipeline

Epidermolysis Bullosa Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key epidermolysis bullosa companies, including Abeona Therapeutics, Castle Creek Biosciences, RHEACELL, Aegle Therapeutics, Phoenix Tissue Repair, Inc., Lenus Therapeutics, LLC, Wings Therapeutics Inc., Krystal Biotech, Inc., Onconova Therapeutics, Inc., InMed Pharmaceuticals Inc., Constant Therapeutics, Kangstem Biotech, ProQR Therapeutics, Ishin Pharmaceutical, among others.

Dystrophic Epidermolysis Bullosa Pipeline

Dystrophic Epidermolysis Bullosa Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, including clinical and non-clinical stage products, and the key dystrophic epidermolysis bullosa companies, including Phoenix Tissue Repair, Castle Creek Biosciences, Phoenicis Therapeutics, Aegle Therapeutics, RHEACELL GmbH & Co. KG, Anterogen Co., Ltd., Abeona Therapeutics, Inc, InMed Pharmaceuticals, BridgeBio Inc., Eloxx Pharmaceuticals, Relief Therapeutics, Quoin Pharmaceuticals, among others.

Dystrophic Epidermolysis Bullosa Market

Dystrophic Epidermolysis Bullosa Market Insights, Epidemiology, and Market Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key dystrophic epidermolysis bullosa companies, including Castle Creek Biosciences, Amryth Pharma, Krystal Biotech, Abeona Therapeutics, BridgeBio, Phoenix Tissue Repair, among others.

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

Contact Us

Shruti Thakur
info@delveinsight.com   
+1(919)321-6187 
www.delveinsight.com     

Logo: https://mma.prnewswire.com/media/1082265/3528414/DelveInsight_Logo.jpg 

Modal title

Also from this source

Comprehensive Lewy Body Dementia Market Analysis of Evolving Trends and Anticipated Growth Trajectory During the Forecast Period (2025-2034) | DelveInsight

Comprehensive Lewy Body Dementia Market Analysis of Evolving Trends and Anticipated Growth Trajectory During the Forecast Period (2025-2034) | DelveInsight

Lewy body dementia (LBD) is a progressive neurological condition characterized by the accumulation of abnormal alpha-synuclein protein in the brain....

Anti-GPC3 Therapies Market Gains Traction with Key Players Advancing Pipeline for Hepatocellular Carcinoma, Non-Small Cell Lung Cancer, Gastric Cancer, and Others | DelveInsight

Anti-GPC3 Therapies Market Gains Traction with Key Players Advancing Pipeline for Hepatocellular Carcinoma, Non-Small Cell Lung Cancer, Gastric Cancer, and Others | DelveInsight

DelveInsight's Anti-GPC3 Targeted Therapies Market Size, Target Population, Competitive Landscape & Market Forecast report includes a comprehensive...

More Releases From This Source

Explore

Health Care & Hospitals

Health Care & Hospitals

Medical Pharmaceuticals

Medical Pharmaceuticals

News Releases in Similar Topics

Contact PR Newswire

  • +44 (0)20 7454 5110
    from 8 AM - 5:30 PM GMT
  • General Enquiries
  • Media Enquiries
  • Partnerships

Products

  • Content Distribution
  • Multimedia Services
  • Disclosure Services
  • Cision Communications Cloud®

About

  • About PR Newswire
  • About Cision
  • Partnering Opportunities
  • Careers
  • Accessibility Statement
  • APAC
  • APAC - Simplified Chinese
  • APAC - Traditional Chinese
  • Brazil
  • Canada
  • Czech
  • Denmark
  • Finland
  • France
  • Germany
  • India
  • Indonesia
  • Israel
  • Japan
  • Korea
  • Mexico
  • Middle East
  • Middle East - Arabic
  • Netherlands
  • Norway
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • Sweden
  • United States
  • Vietnam

My Services

  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
  • Data Privacy

Do not sell or share my personal information:

  • Submit via Privacy@cision.com 
  • Call Privacy toll-free: 877-297-8921

Contact PR Newswire

Products

About

My Services
  • All News Releases
  • Customer Portal
  • Resources
  • Blog
  • Journalists
+44 (0)20 7454 5110
from 8 AM - 5:30 PM GMT
  • Terms of Use
  • Privacy Policy
  • Information Security Policy
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 PR Newswire Europe Limited. All Rights Reserved. A Cision company.